| Literature DB >> 36081682 |
Nnaemeka T Onyishi1, Samuel R Ohayi1.
Abstract
Objective: To estimate the prevalence of cutaneous SCC and BCC in all histologically confirmed skin cancer lesions in African albinos.The following five databases are as follows: African Journals Online (AJOL), PubMed, Europe PMC, and Google Scholar were searched for relevant articles. Study Selection: included studies were case series and cross-sectional studies of histologically confirmed skin cancers in African albinos. Data extraction and synthesis: data extraction and synthesis was informed by the meta-analysis of observational studies in epidemiology guideline. By random effect meta-analysis, we calculated the pooled prevalence of SCC and BCC in skin cancer lesions of the African albinos. Result: We abstracted 695 skin cancer lesions from 540 African albinos (275 male and 241 female albinos with sex not stated in 24 subjects). There were 419 SCCs and 249 BCCs. By meta-analysis, the pooled prevalence of SCC is 64% (95% CI; 50-77%). The prevalence for BCC is 31% (95% CI; 19-45%).Entities:
Year: 2022 PMID: 36081682 PMCID: PMC9448621 DOI: 10.1155/2022/5014610
Source DB: PubMed Journal: J Skin Cancer ISSN: 2090-2913
Risk of bias assessment tool [19]].
|
|
| i. Cases were selected over a specified range of period? 2 points |
| ii. Selection approach unclear? 1 point |
|
|
| i. Clinical records? 2 points |
| ii. Self-report or other methods? 1point |
|
|
| i. Cases described in sufficient details? 2 points |
| ii. Cases scanty with some missing information? 1point |
Figure 1PRISMA flow chart of the article selection process.
Included studies, country of study, number of albinos, and skin cancer type.
| Author; year | Country | No. of albinos with skin cancer | Skin cancer type | Males | Females | ||||
|---|---|---|---|---|---|---|---|---|---|
| SCC | BCC | CM | Others | Total | |||||
| Shapiro MP; 1953 | South Africa | 12 | 9 | 3 | 0 | 0 | 12 | 8 | 4 |
| Datubo–Brown DD; 1991 | Nigeria | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 |
| Yakubu A; 1993 | Nigeria | 18 | 15 | 3 | 0 | 0 | 18 | 12 | 6 |
| Oluwasanmi J; 1969 | Nigeria | 15 | 8 | 6 | 0 | 1 | 15 | 12 | 3 |
| Alexander G; 1981 | Tanzania | 10 | 21 | 0 | 0 | 0 | 21 | 9 | 1 |
| Lookingbill DP; 1995 | Tanzania | 10 | 7 | 3 | 0 | 1 | 11 | 5 | 5 |
| Asuquo ME; 2010 | Nigeria | 9 | 5 | 5 | 1 | 0 | 11 | 5 | 4 |
| OparaK O; 2010 | Nigeria | 20 | 32 | 5 | 0 | 1 | 38 | 10 | 10 |
| Bangaly T; 2019 | Guinea | 30 | 40 | 0 | 0 | 1 | 41 | 12 | 18 |
| Kiprono AS; 2014 | Tanzania | 86 | 72 | 61 | 1 | 0 | 134 | 41 | 45 |
| Mabula JB; 2012 | Tanzania | 64 | 48 | 15 | 1 | 0 | 64 | 38 | 26 |
| Emadi SE; 2017 | Kenya | 20 | 8 | 15 | 0 | 0 | 23 | 13 | 7 |
| Nthumba PM; 2011 | Kenya | 8 | 0 | 8 | 0 | 0 | 8 | 5 | 3 |
| Enechukwu AN; 2020 | Nigeria | 18 | 9 | 22 | 0 | 9 | 40 | 9 | 9 |
| Awe OO; 2018 | Nigeria | 22 | 15 | 5 | 2 | 0 | 22 | 11 | 11 |
| Aluko Olokun; 2015 | Nigeria | 35 | 12 | 16 | 0 | 7 | 35 | 17 | 18 |
| Oripelaye MM; 2018 | Nigeria | 12 | 8 | 4 | 0 | 0 | 12 | 0 | 0 |
| Asuquo ME; 2013 | Nigeria | 4 | 7 | 0 | 0 | 0 | 7 | 2 | 2 |
| Madubuko R; 2018 | Nigeria | 9 | 8 | 1 | 0 | 0 | 9 | 0 | 0 |
| Adegbidi H; 2007 | Benin Republic | 5 | 1 | 12 | 0 | 0 | 13 | 3 | 2 |
| Saka B; 2020 | Togo | 33 | 21 | 31 | 0 | 2 | 54 | 17 | 16 |
| Okafor CO; 2020 | Nigeria | 86 | 64 | 33 | 0 | 0 | 97 | 38 | 48 |
| Chidothe IA; 2014 | Malawi | 7 | 6 | 1 | 0 | 0 | 7 | 6 | 1 |
SCC: squamous cell carcinoma; BCC: basal cell carcinoma; CM: cutaneous melanoma.
Risk of bias assessment score for each of the included study.
| 1st Author; study year | A | B | C | Aggregate score | |
|---|---|---|---|---|---|
| Selection | Ascertainment of outcome | Reporting | |||
| 1 | Adegbidi H; 2007 | 2 | 2 | 2 | 6 |
| 2 | Alexander G; 1981 | 1 | 2 | 2 | 5 |
| 3 | Aluko Olokun; 2015 | 1 | 1 | 2 | 4 |
| 4 | Asuquo ME; 2013 | 1 | 2 | 2 | 5 |
| 5 | Asuquo, ME; 2010 | 2 | 2 | 2 | 6 |
| 6 | Awe OO; 2018 | 2 | 2 | 1 | 5 |
| 7 | Bangaly T; 2019 | 2 | 2 | 2 | 6 |
| 8 | Chidothe IA; 2014 | 1 | 2 | 2 | 5 |
| 9 | Datubo–Brown DD; 1991 | 1 | 2 | 1 | 4 |
| 10 | Emadi SE; 2017 | 2 | 2 | 2 | 6 |
| 11 | Enechukwu AN; 2020 | 2 | 2 | 1 | 5 |
| 12 | Kiprono AS; 2014 | 2 | 2 | 2 | 6 |
| 13 | Lookingbill DP; 1995 | 2 | 2 | 1 | 5 |
| 14 | Mabula JB; 2012 | 2 | 2 | 2 | 6 |
| 15 | Madubuko R; 2018 | 2 | 2 | 2 | 6 |
| 16 | Nthumba PM; 2011 | 1 | 2 | 2 | 5 |
| 17 | Okafor CO; 2O2O | 2 | 2 | 2 | 6 |
| 18 | Oluwasanmi J, 1969 | 2 | 2 | 2 | 6 |
| 19 | Opara KO; 2010 | 2 | 2 | 2 | 6 |
| 20 | Oripelaye MM; 2018 | 1 | 2 | 2 | 5 |
| 21 | Saka B; 2020 | 2 | 2 | 2 | 6 |
| 22 | Shapiro MP, 1953 | 2 | 2 | 2 | 6 |
| 23 | Yakubu A, 1993 | 2 | 2 | 2 | 6 |
Aggregate score: 3, 4 (low quality); 5, 6 (high quality).
Skin cancer type and sex of 540 African albinos with cutaneous malignancy.
| Variable | Frequency |
|---|---|
| Sex | |
| Male | 275 |
| Female | 241 |
| Missing | 24 |
| Total | 540 |
| Skin cancer type | 419 |
| Squamous cell carcinoma | 419 |
| Basal cell carcinoma | 249 |
| Cutaneous melanoma | 5 |
| Others | 22 |
| Total | 695 |
;Some patients presented multifocal cancers: 9 basosquamous carcinoma, 10 adenoid cystic carcinoma, 1 malignant adnexal tumour, 1 sarcoma, and 1 unspecified histology.
Figure 2Forest plot showing the pooled prevalence of squamous cell carcinoma in 23 included studies.
Figure 3Forest plot showing the pooled prevalence of basal cell carcinoma.
Figure 4Funnel plot of the included studies.